1. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501–9.
2. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus. Metabolism 1996;45:1130–5.
3. Cusi K, Cukier S, DeFronzo R, et al. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001;86:1410–7.
4. Halberstam M, Cohen N, Schlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659–66.
5. Goldfine A, Patti M, Zuberi L, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000;49:400–10.
6. Thompson K, Lichter J, LeBel C, et al. Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 2009;103:554–8.
7. Naylor GJ. Vanadium and manic depressive psychosis. Nutr Health 1984;3:79-85 [review].
8. Chakraborty A, Ghosh R, Roy K, et al. Vanadium: a modifier of drug metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology 1995;52:310-4.